Back

Understanding Lesion Progression in a Chronic Model of Cerebral Cavernous Malformations through Combined MRI and Histology

Fisher, D. G.; Sharifi, K. A.; Ulutas, E. Z.; Kumar, J. S.; Kalani, M. Y. S.; Miller, G. W.; Price, R. J.; Tvrdik, P.

2022-11-15 neuroscience
10.1101/2022.11.15.516639 bioRxiv
Show abstract

Cerebral cavernous malformations (CCM), also known as cavernous angiomas, are blood vessel abnormalities comprised of clusters of grossly enlarged and hemorrhage-prone capillaries. The prevalence in the general population, including asymptomatic cases, is estimated to be 0.5%. Some patients develop severe symptoms, including seizures and focal neurologic deficits, while others have no symptoms. The causes of this remarkable presentation heterogeneity within a primarily monogenic disease remain poorly understood. To address this problem, we have established a chronic mouse model of CCM, induced by postnatal ablation of Krit1 with Pdgfb-CreERT. These mice develop CCM lesions gradually over 4-6 months of age throughout of the brain. We examined lesion progression in these mice with T2-weighted 7T MRI protocols. Precise volumetric analysis of individual lesions revealed non-monotonous behavior, with some lesions temporarily growing smaller. However, the cumulative lesional volume invariably increased over time and accelerated after about 3 months. Next, we established a modified protocol for dynamic contrast enhanced (DCE) MR imaging and produced quantitative maps of gadolinium tracer MultiHance in the lesions, indicating a high degree of heterogeneity in lesional permeability. Multivariate comparisons of MRI properties of the lesions with cellular markers for endothelial cells, astrocytes, and microglia revealed that increased cell density surrounding lesions correlates with stability, while increased vasculature within and surrounding lesions may correlate with instability. Our results lay a foundation for better understanding individual lesion properties and provide a comprehensive pre-clinical platform for testing new drug and gene therapies for controlling CCM.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Fluids and Barriers of the CNS
21 papers in training set
Top 0.1%
18.9%
2
Journal of Cerebral Blood Flow & Metabolism
43 papers in training set
Top 0.1%
14.5%
3
Brain
154 papers in training set
Top 0.6%
8.5%
4
Scientific Reports
3102 papers in training set
Top 14%
6.9%
5
Frontiers in Neuroscience
223 papers in training set
Top 1%
3.7%
50% of probability mass above
6
eLife
5422 papers in training set
Top 25%
3.6%
7
Journal of Thrombosis and Haemostasis
28 papers in training set
Top 0.2%
3.6%
8
Nature Communications
4913 papers in training set
Top 43%
2.8%
9
Brain Communications
147 papers in training set
Top 1%
2.1%
10
NeuroImage
813 papers in training set
Top 4%
1.9%
11
Acta Neuropathologica Communications
81 papers in training set
Top 0.6%
1.7%
12
NeuroImage: Clinical
132 papers in training set
Top 2%
1.7%
13
Cell Reports
1338 papers in training set
Top 24%
1.7%
14
PLOS ONE
4510 papers in training set
Top 53%
1.7%
15
JCI Insight
241 papers in training set
Top 4%
1.7%
16
Experimental Neurology
57 papers in training set
Top 0.7%
1.7%
17
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 36%
1.3%
18
Theranostics
33 papers in training set
Top 0.9%
1.2%
19
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.1%
20
Stroke
35 papers in training set
Top 0.7%
1.0%
21
PLOS Biology
408 papers in training set
Top 21%
0.7%
22
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 3%
0.6%
23
Neurobiology of Disease
134 papers in training set
Top 5%
0.6%
24
Neurophotonics
37 papers in training set
Top 0.8%
0.5%
25
iScience
1063 papers in training set
Top 40%
0.5%
26
Communications Biology
886 papers in training set
Top 32%
0.5%